| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | ChIP:1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Histone H3.1; Histone H3; HIST1H3A; H3K9me2; ;DiMethyl-Histone H3 (K9) |
| WB Predicted band size | 15 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Histone H3.1 around the methylation site of K80 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是三篇涉及Histone H3K9me2(dimethylK9)抗体的代表性文献，内容涵盖其应用方向及研究意义：
---
1. **文献名称**：*Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain*
**作者**：Bannister AJ, et al.
**摘要**：该研究首次揭示HP1蛋白通过其chromo结构域特异性识别H3K9me2/me3修饰，并阐明了该修饰在异染色质形成及基因沉默中的关键作用。实验中采用H3K9me2抗体进行染色质免疫沉淀(ChIP)验证结合位点。
---
2. **文献名称**：*Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer*
**作者**：Fraga MF, et al.
**摘要**：研究通过H3K9me2及H4K16ac等抗体进行免疫组化分析，发现多种癌症中H3K9me2的异常分布与表观遗传失调相关，提示其作为肿瘤生物标志物的潜力。
---
3. **文献名称**：*Genome-wide maps of histone modifications in pluripotent and lineage-committed cells*
**作者**：Mikkelsen TS, et al.
**摘要**：通过ChIP-seq结合H3K9me2抗体，绘制多能干细胞与分化细胞的全基因组组蛋白修饰图谱，揭示H3K9me2在维持染色质动态平衡及细胞命运决定中的调控网络。
---
**备注**：上述文献均发表于高影响力期刊(如Nature、Cell)，实验中使用H3K9me2抗体作为核心工具，建议通过PubMed或DOI进一步获取全文。如需更多方向(如神经疾病、衰老等)，可补充说明。
Histone H3 (dimethylK9) antibodies are essential tools for studying epigenetic regulation and chromatin dynamics. Histone H3 lysine 9 dimethylation (H3K9me2) is a post-translational modification associated with transcriptional repression and heterochromatin formation. This mark is primarily deposited by histone methyltransferases such as G9a/GLP and SUV39H1. which play roles in gene silencing, X-chromosome inactivation, and maintaining genomic stability. Unlike H3K9me3. which is strongly linked to constitutive heterochromatin, H3K9me2 is enriched in facultative heterochromatin and participates in dynamic gene regulation during development and differentiation.
These antibodies are widely used in chromatin immunoprecipitation (ChIP), immunofluorescence, and Western blotting to investigate epigenetic mechanisms in diseases such as cancer, neurological disorders, and aging. For example, aberrant H3K9me2 patterns have been observed in various cancers, correlating with oncogene activation or tumor suppressor silencing. In stem cell research, they help assess pluripotency and differentiation states by mapping repressive chromatin domains.
Most commercial H3K9me2 antibodies are generated using synthetic peptides corresponding to the dimethylated H3K9 region, followed by affinity purification. Specificity validation typically includes peptide competition assays and knockout cell line controls. Researchers must optimize experimental conditions due to potential cross-reactivity with similar histone modifications (e.g., H3K27me2). Recent advancements in single-cell epigenomic techniques have further expanded applications of these antibodies in mapping chromatin landscapes at high resolution.
×
